Pfizer Completes Acquisition of Seagen

 

• Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer
• To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio^® (avelumab) in the U.S. to the American Association for Cancer Research (AACR)

Read More